Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas
Titel:
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas
Auteur:
Gaudio, E. Tarantelli, C. Kwee, I. Barassi, C. Bernasconi, E. Rinaldi, A. Ponzoni, M. Cascione, L. Targa, A. Stathis, A. Goodstal, S. Zucca, E. Bertoni, F.